完整的粘膜愈合在克罗恩氏病的内镜气球扩张后,可以防止狭窄的进展
Jun Owada1, Kunihiko Oguro1, Tomonori Yano1
1Department of Medicine Division of Gastroenterology Jichi Medical University Tochigi Japan.
DEN open
|April 25, 2025
概括
完整的粘膜愈合是克罗恩病患者内镜气球扩张后预防肠狭窄进展的关键. 实现这种愈合可以显著减少复,避免重复手术或手术.
科学领域:
- 胃肠病学 胃肠病学
- 内镜检查是指内镜检查.
- 炎症性肠道疾病 炎症性肠病
背景情况:
- 透视气球扩张 (EBD) 是克罗恩病 (CD) 肠道狭窄的主要治疗方法.
- 缩症和需要重复干预的需要是EBD后的常见挑战.
- 影响复缩的因素,特别是收缩直径,仍未得到充分研究.
研究的目的:
- 在CD相关的小肠狭窄症中,在EBD后完全的粘膜愈合和减少的缩之间进行前性验证.
- 准确测量狭窄直径,并确定EBD后进展的预测因素.
主要方法:
- 一个单一中心前性研究,涉及41名患有CD和经历EBD的小肠收缩的患者.
- 使用校准透明罩进行测量的狭窄直径.
- 多变量分析以确定影响狭窄进展的因素.
主要成果:
- 73%的患者经历了收缩进展.
- 会议之间的的存在是一个显著的危险因素 (OR 7.59,p=0.031).
- 完全的粘膜愈合与最窄的狭窄直径显著增加相关 (+1.5毫米,p=0.00089).
结论:
- 完整的粘膜愈合对于预防克罗恩病中EBD后狭窄性进展至关重要.
- 这一发现支持优化粘膜愈合,以改善EBD的长期结果.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
59
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
59
Esophageal Strictures-II: Clinical Features and Management
19
Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
19
Chronic Bowel Disorders: Introduction
310
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
310
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
325
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
325
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
301
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
301
Peptic Ulcer Disease IV: Management
49
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
49


